Tarlatamab combined with PD-L1 inhibitors shows potential in improving survival for ES-SCLC, with a median OS of 25.3 months. The combination may bypass tumor immune evasion by redirecting T-cells to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results